| Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker (NCT05763511) | University of Aarhus | 2022-07-01 |
| Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O) (NCT05403177) | University Health Network, Toronto | 2022-06-23 |
| Gynaecology Exercise and Mindfulness Study (NCT05561413) | University of Ulster | 2022-06-14 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (NCT05296564) | Hadassah Medical Organization | 2022-04-01 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (NCT05187338) | Second Affiliated Hospital of Guangzhou Medical University | 2021-11-01 |
| Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer (NCT05059782) | Xi'an Jiaotong University | 2021-10-10 |
| The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib (NCT05081765) | Poznan University of Medical Sciences | 2021-09-20 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1 (NCT04523116) | University of Manchester | 2021-01-14 |
| Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK (NCT04532645) | AstraZeneca | 2021-01-07 |
| Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (NCT04000880) | University of Alabama at Birmingham | 2020-03-04 |
| ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (NCT04205227) | ENB Therapeutics, Inc | 2020-02-18 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy (NCT03740984) | Dr. Horst Schmidt Klinik GmbH | 2018-02-01 |
| Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies (NCT03199586) | Novita Pharmaceuticals, Inc. | 2017-12-21 |
| Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery (NCT02997553) | Institut de Cancérologie de Lorraine | 2017-11-29 |
| Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. (NCT03245736) | Seagen Inc. | 2017-08-23 |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer (NCT03162562) | CanariaBio Inc. | 2017-05-30 |
| The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. (NCT03384511) | Shandong Cancer Hospital and Institute | 2016-09-30 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (NCT02582931) | Washington University School of Medicine | 2015-12-02 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors (NCT02552121) | Seagen Inc. | 2015-11-30 |
| Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (NCT02432378) | Roswell Park Cancer Institute | 2015-09-04 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (NCT02069158) | Cristiana Sessa | 2014-04-01 |
| Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors (NCT02001623) | Seagen Inc. | 2013-11-30 |
| Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma (NCT00193297) | SCRI Development Innovations, LLC | 2002-02-01 |